AbCellera Biologics (ABCL)

AbCellera Biologics (ABCL) Financial Statements


AbCellera Biologics Financial Overview

AbCellera Biologics's market cap is currently ―. The company's EPS TTM is $-0.506; its P/E ratio is -9.97; AbCellera Biologics is scheduled to report earnings on May 8, 2024, and the estimated EPS forecast is $-0.12. See an overview of income statement, balance sheet, and cash flow financials.
Jun 23Mar 23Dec 22Sep 22Jun 22
Income Statement-
Total Revenue$ 10.06K$ 15.79K$ 21.55M$ 101.38M$ 45.92M
Gross Profit$ 10.06K$ 15.79K$ 19.99M$ 86.35M$ 40.71M
EBIT$ -38.00K$ -48.15K$ -20.02M$ 39.88M$ -6.86M
EBITDA$ -30.75K$ -41.03K$ -4.66M$ 46.61M$ -820.00K
Net Income Common Stockholders$ -30.53K$ -40.11K$ -29.89M$ 26.62M$ -6.79M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 795.69K$ 796.50K$ 886.49M$ 868.21M$ 1.02B
Total Assets$ 1.54M$ 1.50M$ 1.54B$ 1.55B$ 1.59B
Total Debt$ 84.03K$ 83.13K$ 82.26M$ 76.11M$ 36.78M
Net Debt$ -711.66K$ -713.36K$ -804.23M$ -792.10M$ -985.49M
Total Liabilities$ 342.34K$ 289.42K$ 307.63M$ 302.24M$ 380.93M
Stockholders Equity$ 1.19M$ 1.21M$ 1.23B$ 1.25B$ 1.21B
Cash Flow-
Free Cash Flow$ -7.30K$ -59.05K$ 18.58M$ -141.30M$ 241.69M
Operating Cash Flow$ 19.90K$ -44.06K$ 30.91M$ -126.79M$ 273.01M
Investing Cash Flow$ -34.39K$ -149.61K$ -17.06M$ -281.99M$ -27.20M
Financing Cash Flow$ 419.00$ -458.00$ 349.00K$ -19.00K$ 1.17M
Currency in USD

AbCellera Biologics Earnings and Revenue History

AbCellera Biologics Debt to Assets

AbCellera Biologics Cash Flow

AbCellera Biologics Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis